Edith D. van der Meijden

Author

Also Known As

E D Van der Meijden, E D van der Meijden, E. D. van der Meijden, E.D. van der Meijden, Edith D van der Meijden, Edith D. Van Der Meijden, Edith D. van der Meijden, Johan Verhagen

Publications

672

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center Friedrich-Alexander-Universität Erlangen-Nürnberg Universitätsklinikum Erlangen Radboud Institute for Molecular Life Sciences Radboud University Nijmegen

About

Edith D. van der Meijden is an author at Leiden University Medical Center specializing in pathology, histocompatibility, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	152
2	Cell Biology	2	2	152
3	Immunology	2	2	152
4	Cellular Therapies	1	1	67
5	Marrow Transplantation	1	1	67

Edith D. van der Meijden

Publications

621

Citations

H-Index

Page 1

	Year	Citations
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing Wibowo Arindrarto, Daniel Borràs, Ruben A. L. de Groen, Leukemia	2020	100
High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning Cornelis A.M. van Bergen, Caroline E. Rutten, Edith D. van der Meijden, Cancer Research HistocompatibilityHlaImmunologyPathologyAntigen Processing	2010	85
Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity Anita N. Stumpf, Edith D. van der Meijden, Cornelis A.M. van Bergen, Blood	2009	69
Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity Marieke Griffioen, Edith D. van der Meijden, Elisabeth H. Slager, Proceedings of the National Academy of Sciences HistocompatibilityCell TherapyHla ImmunogeneticsImmunologyPathology	2008	67
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Elisabeth H. Slager, M. Willy Honders, Edith D. van der Meijden, Blood	2006	65
Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential Johan Verhagen, Edith D. van der Meijden, Vanessa Lang, Clinical & Experimental Immunology	2021	44
Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO Anita N. Kremer, Edith D. van der Meijden, Maria W. Honders, Blood	2012	36
Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity Marieke Griffioen, M. Willy Honders, Edith D. van der Meijden, Haematologica	2012	33
HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Edith D. van der Meijden, Biology of Blood and Marrow Transplantation	2010	30
Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Edith D. van der Meijden, Blood	2010	22

Page 1